U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06800313) titled 'A Study of HLD-0915 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)' on Jan. 20.
Brief Summary: Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recommended dose for expansion (RDE) has been determined in Phase 1 of the trial.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer Metastatic Disease
Prostate Cancer (Adenocarcinoma)
Intervention:
DRUG: HLD-0915
A treatment cycle consists of 21 days. Treatment may continue until dis...